PSA test helps predicting biopsy need and low risk prostate cancer
Mayo Clinic study: PSA test valuable in predicting biopsy need, low-risk prostate cancer – The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. The findings were released during a meeting of the North Central Section of the American Urological Association in Rancho Mirage, California, US.